arrow
N

Nicola Fracchiolla

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
H指数:32
被引数:4,523

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia

免疫和细胞学因素对急性髓系白血病中HMA-venetoclax方案疗效的影响

2026-10-140
OAAI
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

非适应证急性髓系白血病患者接受维奈克拉联合去甲基化药物的疗效:GIMEMA AML2320试验结果

2026-09-050
PRE
Real-Life Study on Gilteritinib-Related Infections (GilteRInf): An Italian SEIFEM Study

Gilteritinib相关感染的Real-Life研究(GilteRInf):一项意大利SEIFEM研究

2026-07-280
OAAI
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
2026-01-130
OAAI
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
2025-11-120
PRE
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study

Venetoclax联合去甲基化药物作为异基因干细胞移植治疗复发/难治性急性髓系白血病的有效桥梁疗法:AVALON研究的一项亚组分析

2025-11-010
OAAI
Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity

10年来血液病患者的病毒性呼吸道感染:流行病学及其对疾病严重程度的影响

2025-10-010
PRE
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group

培门冬酶(Pegaspargase)在55岁及以上急性淋巴细胞白血病患者的给药方案与耐受性研究:LAL1913方案的子分析,Campus ALL研究组。

2025-08-270
OAAI
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group
2024-08-080
PRE
Ponatinib alone or with chemo-immunotherapy in heavily pre treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study
2024-08-010
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
2023-08-119
OAAI
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
2023-07-282
OAAI
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

tixagevimab/cilgavimab对血液系统恶性肿瘤和新型冠状病毒肺炎患者的被动暴露前预防接种: EPICOVIDEHA注册表中的配对分析

2023-04-0113
OAAI